The expanding options for front-line treatment in patients with newly diagnosed CML

Critical Reviews in Oncology/Hematology

Volumn 84, Issue 2, 2012, Pages 287-299

  Pinilla Ibarz, Javier ^a   Flinn, Ian ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Chronic myeloid leukemia; Dasatinib; Front line setting; Imatinib; Nilotinib; Tyrosine kinase therapy

Indexed keywords

ALPHA INTERFERON; BOSUTINIB; CYTARABINE; DANUSERTIB; DASATINIB; IMATINIB; NILOTINIB; PEGINTERFERON ALPHA2A; PONATINIB; REBASTINIB; XL 228;

ALOPECIA; BCR ABL FUSION GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; EVENT FREE SURVIVAL; FAILURE FREE SURVIVAL; FLUID RETENTION; FUSION GENE; GENE MUTATION; HEART DISEASE; HUMAN; MUSCLE SPASM; NAUSEA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; PRURITUS; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 84867894046     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.03.005     Document Type: Review

References (81)

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia v.2.2012. Available at: nccn.org.
2. Faderl S., Talpaz M., Estrov Z., Kantarjian H.M. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999, 131:207-219.
3. Preudhomme C., Guilhot J., Nicolini F.E., et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010, 363:2511-2521.
4. Hehlmann R., Heimpel H., Hasford J., et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994, 84:4064-4077.
5. Kantarjian H.M., O'Brien S., Cortes J.E., et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003, 97:1033-1041.
6. Akahane D., Ito Y., Sumi M., Tauchi T., Kimura Y., Ohyashiki K. Relapse of chronic myeloid leukemia-chronic phase 14 years after allogeneic hematopoietic stem cell transplantation. Int J Hematol 2008, 88:119-120.
7. Kearney P., Suter M., Biggs J.C. Rapid clonal development in a relapsed CML 11 years post replete allogeneic bone marrow transplantation. Leuk Res 2002, 26:111-115.
8. Robin M., Guardiola P., Devergie A., et al. A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors. Leukemia 2005, 19:1613-1620.
9. Yong A.S.M., Goldman J.M. Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999, 23:827-828.
10. Fernandez H.F., Kharfan-Dabaja M.A. Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities. Cancer Control 2009, 16:153-157.
11. Deininger M., O'Brien S.G., Guilhot F., et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009, 114:1126.
12. Gambacorti-Passerini C., Antolini L., Mahon F.X., et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011, 103:553-561.
13. Stegmeier F., Warmuth M., Sellers W.R., Dorsch M. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther 2010, 87:543-552.
14. Agrawal M., Garg R.J., Cortes J., Quintas-Cardama A. Tyrosine kinase inhibitors: the first decade. Curr Hematol Malig Rep 2010, 5:70-80.
15. Gleevec (imatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012, January.
16. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
17. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
18. de Lavallade H., Apperley J.F., Khorashad J.S., et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008, 26:3358-3363.
19. Lucas C.M., Wang L., Austin G.M., et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008, 22:1963-1966.
20. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399-401.
21. Weisberg E., Manley P.W., Breitenstein W., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129-141.
22. Rosti G., Castagnetti F., Gugliotta G., Palandri F., Baccarani M. Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase. Crit Rev Oncol Hematol 2011, [Epub ahead of print].
23. Osborn M., Hughes T. Managing imatinib resistance in chronic myeloid leukaemia. Curr Opin Hematol 2010, 17:97-103.
24. White D., Saunders V., Grigg A., et al. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 2007, 25:4445-4451.
25. Saglio G., Kim D.W., Issaragrisil S., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
26. Kantarjian H., Shah N.P., Hochhaus A., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
27. Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011, November.
28. Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2011, October.
29. Fava C., Kantarjian H., Cortes J., Jabbour E. Development and targeted use of nilotinib in chronic myeloid leukemia. Drug Des Dev Ther 2009, 2:233-243.
30. Manley P.W., Stiefl N., Cowan-Jacob S.W., et al. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem 2010, 18:6977-6986.
31. Valent P., Gastl G., Geissler K., et al. Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions. Crit Rev Oncol Hematol 2011, [Epub ahead of print].
32. Rosti G., Castagnetti F., Gugliotta G., et al. Excellent outcomes at 3 years with nilotinib 800mg daily in early chronic phase, Ph+ chronic myeloid leukemia (CML): results of a phase 2 GIMEMA CML WP Clinical Trial. Blood 2010, 116:359.
33. Hughes T.P., Hochhaus A., Saglio G., et al. ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Blood 2010, 116:207.
34. Kantarjian H.M., Hochhaus A., Saglio G., et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011, 12:841-851.
35. Lenaerts T., Castagnetti F., Traulsen A., Pacheco J.M., Rosti G., Dingli D. Explaining the in vitro and in vivo differences in leukemia therapy. Cell Cycle 2011, 10:1540-1544.
36. Hochhaus A., Saglio G., Larson R.A., et al. Nilotinib lowers the incidence of BCR-ABL mutations and improves the molecular response kinetics compared with imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia (CML). Blood 2010, 116:3431.
37. Larson R.A., Hochhaus A., Saglio G., et al. Cardiac safety profile of imatinib and nilotinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): results from ENESTnd. Blood 2010, 116:2291.
38. Giles F.J., O'Dwyer M., Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009, 23:1698-1707.
39. Lombardo L.J., Lee F.Y., Chen P., et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47:6658-6661.
40. Cortes J.E., Jones D., O'Brien S., et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010, 28:398-404.
41. Radich J.P., Kopecky K.J., Kamel-Reid S., et al. A randomized phase II trial of dasatinib 100mg vs imatinib 400mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 Intergroup Trial. Blood 2010, 116. LBA-LBA6.
42. Kantarjian H.M., Shah N.P., Cortes J.E., et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012, 119:1123-1129.
43. Sokal J.E., Cox E.B., Baccarani M., et al. Prognostic discrimination in good-risk chronic granulocytic leukemia. Blood 1984, 63:789-799.
44. Hasford J., Pfirrmann M., Hehlmann R., et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998, 90:850-858.
45. Bixby D., Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology 2009, 2009:461-476.
46. Terasawa T., Dahabreh I., Trikalinos T.A. BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. PLoS Curr 2010, 2:RRN1204.
47. White D., Saunders V., Lyons A.B., et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005, 106:2520-2526.
48. Williams L.A., Ault P., Cleeland C.S., et al. Symptom burden in chronic myeloid leukemia (CML). J Clin Oncol 2010, 28:6133.
49. Marin D., Bazeos A., Mahon F.X., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28:2381-2388.
50. Ibrahim A.R., Eliasson L., Apperley J.F., et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for CML patients on long term therapy. Blood 2011, 117:3733-3736.
51. Wu E.Q., Johnson S., Beaulieu N., et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010, 26:61-69.
52. Kantarjian H.M., Larson R.A., Guilhot F., et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009, 115:551-560.
53. Hehlmann R., Lauseker M., Jung-Munkwitz S., et al. Tolerability-adapted imatinib 800mg/d versus 400mg/d versus 400mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011, 29:1634-1642.
54. Hughes T.P., Branford S., White D.L., et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600mg/day of imatinib as initial therapy. Blood 2008, 112:3965-3973.
55. Baccarani M., Druker B.J., Cortes-Franco J., et al. 24 months update of the TOPS study: a phase III, randomized, open-label study of 400mg/d (SD-IM) versus 800mg/d (HD-IM) of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP). Blood 2009, 114:337.
56. Baccarani M., Rosti G., Castagnetti F., et al. Comparison of imatinib 400mg and 800mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009, 113:4497-4504.
57. Deenik W., Janssen J.J., van der Holt B., et al. Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia. Haematologica 2010, 95:914-921.
58. Milojkovic D., Nicholson E., Apperley J.F., et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2010, 95:224-231.
59. Piazza R.G., Magistroni V., Franceschino A., et al. The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with imatinib mesylate predicts for prolonged response at 6 years. Blood Cells Mol Dis 2006, 37:111-115.
60. Tam C.S., Kantarjian H., Garcia-Manero G., et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 2008, 112:516-518.
61. Breccia M., Alimena G. The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era. Crit Rev Oncol Hematol 2011, 79:135-143.
62. Hughes T.P., Hochhaus A., Branford S., et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon versus STI571 (IRIS). Blood 2010, 116:3758-3765.
63. Baccarani M., Cortes J., Pane F., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
64. Marin D., Ibrahim A.R., Lucas C., et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012, 30:232-238.
65. Hanfstein B, Müller MC, Erben P, et al. for The SAKK, for The German CML Study Group. Molecular and cytogenetic response after 3 months of imatinib treatment is predictive for the risk of disease progression and death in newly diagnosed chronic myeloid leukemia patients - a follow-up analysis of the German CML Study IV. In: ASH Annual Meeting Abstracts. Blood 2011;118:783.
66. Latagliata R., Breccia M., Carmosino I., et al. Complete cytogenetic response after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia. Blood 2011, 118:3783.
67. 400, nilotinib and dasatinib is a major prognostic factor for failure-free and progression-free survival. Blood 2011, 118:1684.
68. Hochhaus A., Saglio G., Chuah C., et al. Dasatinib and imatinib-induced reductions in BCR-ABL transcript levels below 10% at 3 months are associated with improved responses in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): analysis of molecular response kinetics in the DASISION trial. Blood 2011, 118:2767.
69. Marin D., Hedgley C., Clark R.E., et al. The predictive value of early molecular response in chronic phase CML patients treated with dasatinib first line therapy. Blood 2011, 118:785.
70. Hughes T.P., Branford S. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. Hematol Am Soc Hematol Educ Program 2009, 477-487.
71. Cross N.C. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009, 22:355-365.
72. Mahon F-X., Réa D., Guilhot J., et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, Multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010, 11:1029-1035.
73. Gambacorti-Passerini C., Kantarjian H., Bruemmendorf T., et al. Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph+ ALL. ASH Annual Meeting Abstracts, vol. 110 2007, 473.
74. Cortes J.E., Kantarjian H.M., Brümmendorf T.H., et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011, 118:4567-4576.
75. Cortes J., Talpaz M., Bixby D., et al. A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings. ASH Annual Meeting Abstracts, vol. 116 2010, 210.
76. Cortes J.E., Talpaz M., Kantarjian H.M., et al. A phase 1 study of DCC-2036, a novel oral inhibitor of BCR-ABL kinase, in patients with Philadelphia chromosome positive (Ph+) leukemias including patients with T315I mutation. Blood 2011, 118:601.
77. Eide C.A., Adrian L.T., Tyner J.W., et al. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res 2011, 71:3189-3195.
78. Gontarewicz A., Brümmendorf T.H. Danusertib (formerly PHA-739358) - a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. Recent Results Cancer Res 2010, 184:199-214.
79. Quintás-Cardama A., Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009, 113:1619-1630.
80. Gambacorti-Passerini C., Cortes J.E., Khoury H.J., et al. Safety and efficacy of bosutinib in patients with AP and BP CML and Ph+ ALL following resistance/intolerance to imatinib and other TKIs: update from study SKI-200. J Clin Oncol 2010, 28:6509.
81. Cortes J.E., Jones D., O'Brien S., et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010, 28:392-397.